FindTrial
Sign In

Pertuzumab Injection

DRUG4 trials

Sponsors

DualityBio Inc., RemeGen Co., Ltd., University of Chicago, Jiangsu HengRui Medicine Co., Ltd.

Conditions

Breast CancerEarly-stage or Locally Advanced HER2-positive Breast CancerHER2-positive Advanced Solid TumorHER2-positive Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast

Phase 1

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
RecruitingNCT05150691
DualityBio Inc.HER2-positive Advanced Solid Tumor
Start: 2022-01-31End: 2027-10-01Target: 796Updated: 2026-01-28

Phase 2

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
RecruitingNCT06178159
RemeGen Co., Ltd.Breast Cancer
Start: 2023-11-28End: 2026-12-31Target: 40Updated: 2025-10-01
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
RecruitingNCT06348134
University of ChicagoBreast Cancer, HER2-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Start: 2025-03-18End: 2036-07-01Target: 74Updated: 2026-02-17

Phase 3

A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer
RecruitingNCT07196774
Jiangsu HengRui Medicine Co., Ltd.Early-stage or Locally Advanced HER2-positive Breast Cancer
Start: 2025-10-23End: 2028-12-01Target: 740Updated: 2026-01-30

Related Papers

Safety and efficacy of neoadjuvant disitamab vedotin in combination with pertuzumab with or without toripalimab for HER2-positive breast cancer: An open-label phase II trial.
Journal of Clinical Oncology2025-05-28
Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study.
Journal of Clinical Oncology2023-06-0113 citations
Abstract CT247: A Phase 1/2a, multicenter, open-label, non-randomized first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1303 in patients with advanced/metastatic solid tumors
Cancer Research2023-04-14
Abstract 2793: Preclinical pharmacokinetics in cynomolgus monkeys and first in human dose prediction of DB-1303, a HER2-targeting antibody-drug conjugate
Cancer Research2023-04-04